natgillin/translations-raw huggingface dataset:
The injection was studied in 581 adults with schizophrenia (compared with placebo or injected haloperidol) and 228 manic adults (compared with placebo or injected lorazepam, another medicine used in manic episodes). 
Uporabo zdravila v obliki injekcije so raziskali pri 581 odraslih s shizofrenijo (primerjava s placebom ali injekcijo haloperidola) in 228 maničnih odraslih (primerjava s placebom ali injekcijo lorazepama, še enega zdravila, ki se uporablja pri zdravljenju manične epizode).
The injection was also shown to be more effective than lorazepam (at a relatively low dose) in manic patients, and as effective as haloperidol in schizophrenia. 
Dokazali so tudi, da je injekcija tega zdravila pri maničnih bolnikih učinkovitejša kot lorazepam (pri relativno nizkem odmerku) in pri shizofreniji enako učinkovita kot haloperidol.
Why has Zyprexa been approved? 
Zakaj je bilo zdravilo Zyprexa odobreno?
For the full list of all side effects reported with Zyprexa, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Zyprexa, glejte navodilo za uporabo.
Zyprexa is usually taken by mouth as tablets, but the injection can be used for the rapid control of agitation or disturbed behaviour in adults with schizophrenia or a manic episode, when taking the medicine by mouth is not appropriate. 
Zdravilo Zyprexa se navadno jemlje peroralno v obliki tablet, vendar pa se za hitro obvladovanje vznemirjenosti ali vedenjskih motenj bolnika s shizofrenijo ali manično epizodo lahko uporabi tudi injekcija, kadar peroralno jemanje ni primerno.
In schizophrenia, Zyprexa tablets have been studied in about 3,000 adults, in which their effectiveness was compared with that of placebo (a dummy treatment) or haloperidol (another antipsychotic medicine). 
V primeru shizofrenije so tablete zdravila Zyprexa proučevali pri približno 3 000 odraslih, pri katerih so učinkovitost zdravila primerjali z učinkovitostjo placeba (zdravila brez zdravilne učinkovine) ali haloperidola (drugega antipsihotičnega zdravila).
In all cases, the maximum dose of Zyprexa that can be given in a day, using tablets or injection, is 20 mg. 
V vseh primerih je 20 mg največji dnevni odmerek zdravila Zyprexa, ki ga lahko damo v obliki tablet ali injekcij.
How has Zyprexa been studied? 
Kako je bilo zdravilo Zyprexa raziskano?
What is Zyprexa used for? 
Za kaj se zdravilo Zyprexa uporablja?
How does Zyprexa work? 
Kako zdravilo Zyprexa deluje?
What is Zyprexa? 
Kaj je zdravilo Zyprexa?
How is Zyprexa used? 
Kako se zdravilo Zyprexa uporablja?
Zyprexa tablets were at least as effective as the medicines they were compared with for the treatment of schizophrenia (haloperidol), the treatment of moderate to severe manic episodes 
Tablete zdravila Zyprexa so bile pri zdravljenju shizofrenije (haloperidol), zdravljenju zmernih do težkih maničnih epizod (haloperidol in valproat) in preprečevanju ponovnega pojava bolezni pri bolnikih z bipolarno motnjo (litij) vsaj tako učinkovite kot zdravila, s katerimi so jih primerjali.
The European Commission granted a marketing authorisation valid throughout the European Union for Sprimeo HCT on 23 June 2011. 
Evropska komisija je dovoljenje za promet z zdravilom Sprimeo HCT, veljavno po vsej Evropski uniji, odobrila dne 23. junija 2011.
The recommended dose of Sprimeo HCT is one tablet per day. 
Priporočeni odmerek zdravila Sprimeo HCT je ena tableta na dan.
The full EPAR for Sprimeo HCT can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Sprimeo HCT je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
It should be taken with a light meal preferably at the same time each day, but grapefruit juice should not be taken together with Sprimeo 
Vzeti ga je treba z lahkim obrokom, najbolje vsak dan ob istem času, vendar pa se zdravilo Sprimeo HCT ne sme vzeti skupaj s sokom grenivke.
This is a summary of the European public assessment report (EPAR) for Sprimeo HCT. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Sprimeo HCT.
The studies lasted for between eight weeks and a year, and the main measure of effectiveness was the change in blood pressure either during the resting phase of the heartbeat (diastolic) or when the chambers of the heart were contracting (systolic). 
Študije so trajale od osem tednov do enega leta, glavno merilo učinkovitosti pa je bila sprememba krvnega tlaka med mirovalno fazo srčnega utripa (diastolični tlak) ali med krčenjem srčnih komor (sistolični tlak).
The most common side effect with Sprimeo HCT (seen in between 1 and 10 patients in 100) is diarrhoea. 
Najpogostejši neželeni učinek zdravila Sprimeo HCT (opažen pri 1 do 10 bolnikih od 100) je driska.
For more information about treatment with Sprimeo HCT, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Sprimeo HCT preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
After two to four weeks of taking Sprimeo HCT, the dose can be increased in patients whose blood pressure remains uncontrolled. 
Po dveh do štirih tednih jemanja zdravila Sprimeo HCT se lahko odmerek poveča pri bolnikih, pri katerih krvni tlak še vedno ni uravnan.
Sprimeo HCT is used to treat essential hypertension (high blood pressure) in adults. 
Zdravilo Sprimeo HCT se uporablja za zdravljenje esencialne hipertenzije (visokega krvnega tlaka) pri odraslih.
The CHMP decided that Sprimeo HCT's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Sprimeo HCT večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Sprimeo HCT was more effective than placebo in reducing blood pressure. 
Zdravilo Sprimeo HCT je bilo pri zniževanju krvnega tlaka učinkovitejše od placeba.
What benefit has Sprimeo HCT shown during the studies? 
Kakšne koristi je zdravilo Sprimeo HCT izkazalo med študijami?
Other information about Sprimeo HCT 
Druge informacije o zdravilu Sprimeo HCT
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Sprimeo HCT. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Sprimeo HCT, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
It must not be taken with ciclosporin, itraconazole, or other medicines known as ‘potent P-glycoprotein inhibitors' (such as quinidine). 
Ne sme se jemati skupaj s ciklosporinom, itrakonazolom ali drugimi zdravili, znanimi kot „močni zaviralci Pglikoproteina“ (kot je kinidin).
Three additional studies were carried out to show that the active substances were absorbed in the body in the same way when they taken as separate tablets and as Sprimeo HCT. 
Izvedene so bile še tri dodatne študije, s katerimi je bilo dokazano, da se zdravilni učinkovini, ki se jemljeta v obliki ločenih tablet, absorbirata v telo enako kot zdravilo Sprimeo HCT.
For the full list of all side effects reported with Sprimeo HCT, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Sprimeo HCT, glejte navodilo za uporabo.
Sprimeo HCT is used in patients whose blood pressure is not adequately controlled by aliskiren or hydrochlorothiazide taken alone. 
Zdravilo Sprimeo HCT se uporablja pri bolnikih, pri katerih krvni tlak ni ustrezno uravnan z jemanjem samo aliskirena ali hidroklorotiazida.
Sprimeo HCT must not be used in people who are hypersensitive (allergic) to aliskiren, hydrochlorothiazide, any of the other ingredients or sulfonamides. 
Zdravila Sprimeo HCT ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) aliskiren, hidroklorotiazid, katero koli drugo sestavino zdravila ali sulfonamide.
The company presented information used in the assessment of aliskiren and from the published literature to support its application for Sprimeo HCT, as well as information from additional studies. 
Družba je v podporo svoji vlogi za zdravilo Sprimeo HCT predstavila informacije, ki so bile uporabljene pri oceni aliskirena, ter informacije iz objavljene literature in dodatnih študij.
It can also be used in patients whose blood pressure is adequately controlled with aliskiren and hydrochlorothiazide taken as separate tablets, to replace the same doses of the two active substances. 
Lahko pa se uporablja tudi pri bolnikih, pri katerih je krvni tlak ustrezno uravnan z aliskirenom in hidroklorotiazidom, ki ju bolniki jemljejo kot ločeni tableti, za nadomestitev istih odmerkov dveh zdravilnih učinkovin.
Patients previously taking only aliskiren or hydrochlorothiazide may need to take the two substances as separate tablets and adjust the doses before switching to Sprimeo HCT. 
Bolniki, ki so predhodno jemali samo aliskiren ali hidroklorotiazid, bodo morda morali vzeti obe učinkovini v ločenih tabletah in odmerke pred prehodom na zdravilo Sprimeo HCT prilagoditi.
What is the risk associated with Sprimeo HCT? 
Kakšna tveganja so povezana z zdravilom Sprimeo HCT?
Sprimeo HCT in combination with an ‘angiotensin converting enzyme (ACE) inhibitors' or ‘angiotensin receptor blockers' (ARBs) must not be used in patients with diabetes, or moderate or severe kidney impairment. 
Zdravilo Sprimeo HCT se v kombinaciji z zaviralcem angiotenzinske konvertaze ali zaviralcem angiotenzinskih receptorjev ne sme uporabljati pri bolnikih s sladkorno boleznijo oziroma zmerno ali hudo okvaro ledvic.
In patients already adequately controlled with the two active substances, the dose of Sprimeo HCT must contain the same doses of aliskiren and hydrochlorothiazide that the patient was taking before. 
Pri bolnikih, pri katerih je krvni tlak že uravnan z obema zdravilnima učinkovinama, mora odmerek zdravila Sprimeo HCT vsebovati enake odmerke aliskirena in hidroklorotiazida, kot jih je bolnik jemal prej.
Sprimeo HCT is a medicine that contains the active substances aliskiren and hydrochlorothiazide. 
Zdravilo Sprimeo HCT je zdravilo, ki vsebuje zdravilni učinkovini aliskiren in hidroklorotiazid.
Sprimeo HCT contains two active substances, aliskiren and hydrochlorothiazide. 
Zdravilo Sprimeo HCT vsebuje dve zdravilni učinkovini, aliskiren in hidroklorotiazid.
Why has Sprimeo HCT been approved? 
Zakaj je bilo zdravilo Sprimeo HCT odobreno?
What is Sprimeo HCT used for? 
Za kaj se zdravilo Sprimeo HCT uporablja?
How is Sprimeo HCT used? 
Kako se zdravilo Sprimeo HCT uporablja?
What is Sprimeo HCT? 
Kaj je zdravilo Sprimeo HCT?
How does Sprimeo HCT work? 
Kako zdravilo Sprimeo HCT deluje?
How has Sprimeo HCT been studied? 
Kako je bilo zdravilo Sprimeo HCT raziskano?
Both these studies involved women aged 18 to 36 years. 
Ženske v obeh študijah so bile stare od 18 do 36 let.
Further information on Elonva can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/elonva. 
Nadaljnje informacije za zdravilo Elonva so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/elonva.
Elonva received a marketing authorisation valid throughout the European Union on 25 January 2010. 
Za zdravilo Elonva je bilo 25. januarja 2010 izdano dovoljenje za promet, veljavno po vsej EU.
What measures are being taken to ensure the safe and effective use of Elonva? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Elonva?
The European Medicines Agency decided that Elonva's benefits are greater than its risks and it can be authorised for use in the EU.. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Elonva večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
The main measure of effectiveness for these studies was the average number of eggs collected from each woman after treatment. 
Glavno merilo učinkovitosti v teh študijah je bilo povprečno število jajčec, odvzetih posamezni ženski po zdravljenju.
FSH stimulates the production of eggs in the ovaries. 
FSH stimulira nastajanje jajčec v jajčnikih.
Other information about Elonva 
Druge informacije o zdravilu Elonva
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Elonva have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Elonva upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
What benefits of Elonva have been shown in studies? 
Kakšne koristi zdravila Elonva so se pokazale v študijah?
As for all medicines, data on the use of Elonva are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Elonva stalno spremljajo.
Side effects reported with Elonva are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Elonva, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
They will then be fertilised in a laboratory and the resulting embryo is implanted in the womb. 
Nato se v laboratoriju oplodijo in nastali zarodek se vsadi v maternico.
Why is Elonva authorised in the EU? 
Zakaj je bilo zdravilo Elonva odobreno v EU?
It is used together with a gonadotrophin-releasing hormone (GnRH) antagonist (another type of medicine used in fertility treatments). 
Uporablja se skupaj z antagonistom gonadotropin sproščajočega hormona (GnRH) (drugo vrsto zdravila, ki se uporablja pri zdravljenju neplodnosti).
It must also not be used in women with abnormal (not menstrual) bleeding from the vagina without a known cause, fibroids or malformations of the womb that would prevent pregnancy, primary ovarian failure, enlarged ovaries or ovaries with cysts, or in women with risk factors for OHSS such as polycystic ovarian syndrome. 
Prav tako se ne sme uporabljati pri ženskah z nenormalnimi (nemenstrualnimi) vaginalnimi krvavitvami brez znanega vzroka, fibroidi ali malformacijami maternice, ki bi preprečevali nosečnost, primarno odpovedjo jajčnikov, povečanimi jajčniki ali jajčniki s cistami ali pri ženskah z dejavniki tveganja za sindrom OHSS, kot je sindrom policističnih jajčnikov.
An overview of Elonva and why it is authorised in the EU 
Pregled zdravila Elonva in zakaj je odobreno v EU
For more information about using Elonva, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Elonva glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
What are the risks associated with Elonva? 
Kakšna tveganja so povezana z zdravilom Elonva?
The study in women over 60 kg had an additional main effectiveness measure which was the number of women with a successful early pregnancy. 
V študiji pri ženskah s telesno maso nad 60 kg je bilo dodatno glavno merilo učinkovitosti število žensk, pri katerih so zabeležili uspešno zgodnjo fazo nosečnosti.
Elonva is a hormonal medicine used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries. 
Elonva je hormonsko zdravilo, ki se uporablja pri ženskah, ki se zdravijo zaradi neplodnosti, da se v jajčnikih stimulira dozorevanje več kot enega jajčeca naenkrat.
In three main studies involving 3,292 women who needed to have ovarian stimulation, Elonva treatment has been shown to be as effective as treatment with follitropin beta (an FSH medicine also used to stimulate the ovaries). 
V treh glavnih študijah, v katerih je sodelovalo 3 292 žensk, ki so potrebovale stimulacijo jajčnikov, se je zdravljenje z zdravilom Elonva izkazalo za enako učinkovito kot zdravljenje s folitropinom beta (zdravilom s FSH, ki se tudi uporablja za stimulacijo jajčnikov).
The eggs are collected using a surgical procedure. 
Jajčeca se odvzamejo s kirurškim posegom.
OHSS occurs when the ovaries over-respond to treatment, causing abdominal swelling and pain, nausea and diarrhoea. 
Sindrom OHSS se pojavi, ko se jajčniki čezmerno odzovejo na zdravljenje, kar povzroči otekanje trebuha, bolečine v trebuhu, navzejo in drisko.
Elonva can only be obtained with a prescription and treatment should be started under the supervision of a doctor experienced in treating fertility problems. 
Predpisovanje in izdaja zdravila Elonva je le na recept, zdravljenje z njim pa je treba uvesti pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem težav s plodnostjo.
Finally, as soon as three eggs are close to maturation, a single injection of a hormone called human chorionic gonadotropin (hCG) is given to release the mature eggs. 
Ko so tri jajčeca skoraj zrela, se bolnici vbrizga ena injekcija hormona, imenovanega humani horionski gonadotropin (hCG), da se zrela jajčeca sprostijo.
The most common side effects with Elonva (which may affect up to 1 in 10 people) are headache, nausea (feeling sick), tiredness, pelvic pain and discomfort, breast tenderness and ovarian hyperstimulation syndrome (OHSS). 
Najpogostejši neželeni učinki zdravila Elonva (ki se lahko pojavijo pri največ 1 bolnici do 10) so glavobol, navzeja (siljenje na bruhanje), utrujenost, bolečine in neprijeten občutek v medenici, občutljive dojke in sindrom ovarijske hiperstimulacije (OHSS).
It is given once as a single injection under the skin in a dose of 100 or 150 micrograms, depending on age and body weight. 
Injicira se enkrat v podkožje, in sicer kot enojna injekcija v odmerku 100 ali 150 mikrogramov, odvisno od telesne mase bolnice.
In corifollitropin alfa, a peptide (a short chain of amino acids) is attached to the FSH to prolong its activity in the body. 
V korifolitropinu alfa je na FSH vezan peptid (kratka veriga aminokislin), da podaljša njegovo delovanje v telesu.
What is Elonvaand what is it used for? 
Kaj je zdravilo Elonva in za kaj se uporablja?
The active substance in Elonva, corifollitropin alfa, is similar to follicle stimulating hormone (FSH), a natural hormone in the body. 
Učinkovina v zdravilu Elonva, korifolitropin alfa, je podobna naravnemu hormonu v telesu, in sicer folikle stimulirajočemu hormonu (FSH).
For the full list of side effects of Elonva, see the package leaflet. 
Za celoten seznam neželenih učinkov zdravila Elonva glejte navodilo za uporabo.
As a result, a single dose of the medicine can be given to stimulate egg production for seven days, instead of daily injections that would be required with other FSH medicines. 
Zato se lahko za enotedensko stimuliranje nastajanja jajčec injicira en odmerek zdravila, kar nadomesti vsakodnevne injekcije, ki bi bile potrebne pri zdravljenju z drugimi zdravili s FSH.
Seven days after the Elonva injection, if further ovarian stimulation is needed, injections of another medicine similar to Elonva, but suitable for daily injection, may be given. 
Če je potrebno dodatno stimuliranje jajčnikov, se lahko sedem dni po injiciranju zdravila Elonva uporabi injekcija drugega zdravila, ki je podobno zdravilu Elonva, vendar je primerno za vsakodnevno injiciranje.
Elonva contains the active substance corifollitropin alfa. 
Zdravilo Elonva vsebuje učinkovino korifolitropin alfa.
Elonva must not be used in patients with tumours of the ovary, breast, womb, pituitary (a gland located at the base of the brain that produces FSH) or hypothalamus (a region of the brain). 
Zdravila Elonva ne smejo uporabljati bolnice s tumorji jajčnikov, dojk, maternice, hipofize (žleze na možganskem dnu, ki tvori FSH) ali hipotalamusa (predela v možganih).
Elonva is available as a solution for injection. 
Na voljo je v obliki raztopine za injiciranje.
Around 39% of those who received Elonva became pregnant compared with 38% of those treated with follitropin beta. 
Zanosilo je približno 39 % žensk, ki so prejele zdravilo Elonva, in 38 % žensk, ki so prejele folitropin beta.
How does Elonva work? 
Kako zdravilo Elonva deluje?
One of the studies involved women weighing 60 kg or less who received a 100-microgram dose of Elonva, and a second study involved women weighing above 60 kg who received a 150-microgram dose. 
V eno od teh študij so bile vključene ženske s telesno maso pod 60 kg, ki so prejele 100-mikrogramski odmerek zdravila Elonva, v drugo pa ženske s telesno maso nad 60 kg, ki so prejele 150-mikrogramski odmerek.
How is Elonva used? 
Kako se zdravilo Elonva uporablja?
Four or five days after the Elonva injection, depending on how the ovaries have responded, treatment is started with a GnRH antagonist, which prevents the ovaries from releasing their eggs too early. 
Zdravljenje z antagonistom GnRH, ki prepreči prezgodnjo sprostitev jajčec iz jajčnikov, se lahko prične štiri ali pet dni po injiciranju zdravila Elonva, odvisno od odziva jajčnikov.
In the first study in women weighing 60 kg or less, the number of eggs collected from each woman was 13.3 for those treated with Elonva and 10.6 for those treated with follitropin beta. 
V prvi študiji, v kateri so sodelovale ženske s telesno maso 60 kg ali manj, so pri vsaki posameznici, ki se je zdravila z zdravilom Elonva, odvzeli 13,3 jajčeca, medtem ko so jih pri posameznicah, zdravljenih s folitropinom beta, odvzeli 10,6.
In the second study in women weighing above 60 kg, the average number of eggs collected from each woman was 13.8 in those treated with Elonva compared with 12.6 in those treated with follitropin beta. 
V drugi študiji pri ženskah s telesno maso nad 60 kg so tistim, ki so se zdravile z zdravilom Elonva, v povprečju odvzeli 13,8 jajčeca, tistim, ki so se zdravile s folitropinom beta, pa 12,6 jajčeca.
The third study involved women in the age range 35 to 42 years weighing 50 kg or more who were given a 150-microgram dose of Elonva; the main measure of effectiveness in this study was the number of women with a successful early pregnancy, and 24 and 27% of women treated with Elonva and follitropin beta respectively became pregnant. 
Glavno merilo učinkovitosti v tej študiji je bilo število žensk z uspešno zgodnjo nosečnostjo, zanosilo pa je 24 % žensk, ki so bile zdravljene z zdravilom Elonva, in 27 % žensk, zdravljenih s folitropinom beta.
List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the member states 
Dodatek I Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila, predlagateljev, imetnikov dovoljenja za promet z zdravilom v državah članicah
Hungary Baxter Hungary Kft. Népfürdő u. 22. 
Madžarskem Baxter Hungary Kft. Népfürdö u. 22.
Romania BAXTER d.o.o. 
Romunije BAXTER d.o.o.
Poland Baxter Polska SP. z o.o. 
Poljskem Baxter Polska SP. z.o.o.
Netherlands Baxter B.V., Kobaltweg 49, 3542 
Nizozemsko Baxter B.V Kobaltweg 49
Baxter AS Gjerdrumsvei 11 0484 Oslo, Norway 
0484 Oslo, Norway
Latvia 
Latviji
Italy 
Italijo
Greece 
Grčijo
Baxter MédicoFarmacêutica, Lda. 
Portugalskem Baxter Médico Farmacêutica Lda
Irland 
Irska
FINLAND 
Finsko
4 to 1,1% acides aminés 
4 to 1,1% aminokisline
Romania BAXTER HEALTHCARE Ltd., 
Romunije Baxter Healthcare Ltd Caxton Way,
13.60 g/l glucose anhydrate 
13.60 g/l Brezvodna glukoza
Lithuania Baxter Healthcare S.A., Moneen Road, Castlebar County Mayo, Ireland 
Romunije Baxter Healthcare SA, Moneen Road, Castlebar, Co. Mayo, Ireland
Anhydrous glucose 38.6 g/L, sodium chloride 5.67 g/L, sodium lactate 3.92 g/L, calcium chloride dihydrate 0.257 g/L, magnesium chloride hexahydrate 0.152 g/L 
Brezvodna glukoza 38.6 g/L, natrijev klorid 5.67 g/L, natrijev S laktat 3.92 g/L, kalcijev klorid 0,257 g/L, magnezijev klorid 0,152 g/L
Anhydrous glucose 13.6 g/L, sodium chloride 5.67 g/L, sodium-L(+) lactate 3.92 g/L, calcium chloride dihydrate 0.257 g/L, magnesium chloride hexahydrate 0.152 g/L 
Brezvodna glukoza 13.6 g/L, natrijev klorid 5.67 g/L, natrijev S laktat 3.92 g/L, kalcijev klorid 0,257 g/L, magnezijev klorid 0,152 g/L